CrystalGenomics Invites Co., LTD.

A083790

KR7083790006

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
3,130 ^KRW	+0.97%		-0.32%	+12.79%

Apr. 18	Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.	CI
Mar. 27	PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	CI

CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2023

March 15, 2024 at 06:51 am EDT

CrystalGenomics Invites Co., LTD. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was KRW 578.42 million compared to KRW 588.59 million a year ago. Net loss was KRW 48,923.63 million compared to KRW 23,868.95 million a year ago.

Basic loss per share from continuing operations was KRW 644 compared to KRW 323 a year ago. Basic loss per share was KRW 661 compared to KRW 345 a year ago.

Latest news about CrystalGenomics Invites Co., LTD.

Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.	Apr. 17	CI
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	Mar. 26	CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	Mar. 17	CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Hwail Pharmaceutical Co.,Ltd. announced extension to the offering period	Jan. 24	CI
An unknown buyer cancelled the acquisition of 2.40% stake in CrystalGenomics, Inc. from Kumho HT, Inc.	Dec. 13	CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Hwail Pharmaceutical Co.,Ltd. announced that it expects to receive KRW 25.999996662 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.	23-10-11	CI
Crystal Bio Sciences Co., Ltd announced that it has received KRW 10 billion in funding from CrystalGenomics Invites Co., LTD.	23-10-11	CI
CrystalGenomics Invites Co., LTD.(KOSDAQ:A083790) dropped from S&P Global BMI Index	23-08-24	CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
CrystalGenomics, Inc. announced that it has received KRW 62.427998592 billion in funding from New Lake Invites Investment Co., Ltd., Osung Advanced Materials Co., Ltd.	23-06-01	CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
An unknown buyer agreed to acquire approximately 2.40% stake in CrystalGenomics, Inc. from Kumho HT, Inc for KRW 28 billion.	23-03-29	CI
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.	22-11-21	CI
CrystalGenomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
CrystalGenomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
CrystalGenomics, Inc. announced that it has received KRW 5.7075 billion in funding from Kumho HT, Inc	22-08-07	CI
CrystalGenomics, Inc. announced that it expects to receive KRW 5.7075 billion in funding from Kumho HT, Inc	22-07-28	CI
CrystalGenomics, Inc. announced that it has received KRW 21.9999994 billion in funding	22-06-23	CI
CrystalGenomics, Inc. announced that it expects to receive KRW 21.9999994 billion in funding	22-06-12	CI
CrystalGenomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Tranche Update on CrystalGenomics, Inc.'s Equity Buyback Plan announced on February 15, 2022.	22-05-16	CI
Tranche Update on CrystalGenomics, Inc.'s Equity Buyback Plan announced on February 15, 2022.	22-05-16	CI
CrystalGenomics, Inc.'s Equity Buyback announced on February 15, 2022, has expired with 688,603 shares, representing 1.01% for KRW 4,503.53 million.	22-05-15	CI

Chart CrystalGenomics Invites Co., LTD.

Duration

Period

More charts

Company Profile

CG Invites Co Ltd is a Korea-based company principally engaged in the development and manufacturing of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical Research and Development segment is engaged in the research, development and sale of new drugs such as anti-inflammatory painkillers, anticancer drugs, anti-infectives and others. It is also engaged in the real estate rental business. The Pharmaceutical Manufacturing segment is engaged in the manufacture, retail and wholesale of finished drug products. The Other segment is engaged in the manufacture and sale of hot packs and other household items.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CRYSTALGENOMICS INVITES CO., LTD.	+12.79%	174M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals